VERV — Verve Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $462.65m
- -$61.63m
- $32.33m
- 46
- 20
- 51
- 33
Annual income statement for Verve Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 1.94 | 11.8 | 32.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 40.6 | 87.1 | 168 | 235 | 261 |
| Operating Profit | -40.6 | -87.1 | -166 | -223 | -229 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -45.7 | -120 | -157 | -200 | -198 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -45.7 | -120 | -157 | -200 | -199 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -45.7 | -120 | -157 | -200 | -199 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -45.7 | -120 | -157 | -200 | -199 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.991 | -2.48 | -2.91 | -3.12 | -2.35 |
| Dividends per Share |